Document is current
Any future updates will be listed below
-
Authors
Freisem, Dennis https://orcid.org/0009-0008-9755-2261
Rodriguez-Alfonso, Armando A.
Lawrenz, Jan https://orcid.org/0000-0003-3767-7130
Zhou, Zhixuan
Monecke, Thomas
Preising, Nico
Endres, Sascha
Wiese, Sebastian
Ständker, Ludger
Kuan, Seah-Ling
Thal, Dietmar R.
Weil, Tanja
Niessing, Dierk
Barth, Holger
Kirchhoff, Frank https://orcid.org/0000-0002-7052-2360
Harms, Mirja https://orcid.org/0000-0002-5460-5166
Münch, Jan https://orcid.org/0000-0001-7316-7141
Sparrer, Konstantin M. J. https://orcid.org/0000-0002-8682-1779
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (CRC1279, SPP1923, SP 1600/7-1, SP 1600/9-1, CRC1279, CRC1279, CRC1279, CRC1279, INST 40/656-1)
Alexander von Humboldt-Stiftung
Bundesministerium für Bildung und Forschung (IMMUNOMOD)
Universitätsklinikum Ulm
- License Information
-
More Information
Article History
Received: 3 July 2024
Revised: 5 September 2024
Accepted: 10 September 2024
First Online: 17 September 2024
Declarations
:
: DRT collaborated with Novartis Pharma AG (Basel, Switzerland), Probiodrug (Halle (Saale), Germany), GE Healthcare (Amersham, UK), and Janssen Pharmaceutical Companies (Beerse, Belgium). All other authors declare no conflict of interest.
: Ethics permission was given by the local ethics committee of the University of Ulm (274/12).
